Rare Disease Acquisition Due-Diligence | European Market Access Case study

Supporting cross-border pharma acquisition due-diligence strategy through reimbursement risk assessment, market acess and deal-valuation modelling across European markets

Background

• A global biopharma client sought to acquire a rare-disease company with established European infrastructure to expand its geographic footprint
• LatticePoint was engaged to evaluate key pipeline and marketed products included in the acquisition, identifyings risks to deal valuation,  investment priorities and launch optimization requirements
• Our team worked collaboratively alongside other client-appointed consultants to deliver and integrated market access assessment 

LatticePoint Engagement

• Conducts comprehensive pricing strategy review and HTA risk analysis across key European markets
• Assesses quality of evidence packages and value dossier relative to local payer expectations
• Interviews target-company senior leaders for strategic insights, negotiation readiness and launch planning maturity
• Identifies compliance risks and reimbursement planning gaps material to deal valuation
• Estimates in-country and above-country headcount need to optimize launch vs. existing headcount

Acquisition approved by C-suite and board. Deal terms successfully adjusted to incorporate a structured “quiet period” for pricing negotiations, protecting against  sub-optimal reference prices agreed being established prior to deal-closure